cfDNA in pancreatic neuroendocrine carcinoma management with Cushing's syndrome.

Endocrine oncology (Bristol, England) Pub Date : 2021-01-01 DOI:10.1530/EO-21-0012

Laura Gerard, David Barthelemy, Arnaud Gauthier, Valerie Hervieu, Jonathan Lopez, Benjamin Gibert, Helene Lasolle, Laurence Chardon, Jessica Garcia, Gérald Raverot, Léa Payen, Thomas Walter

{"title":"cfDNA in pancreatic neuroendocrine carcinoma management with Cushing's syndrome.","authors":"Laura Gerard, David Barthelemy, Arnaud Gauthier, Valerie Hervieu, Jonathan Lopez, Benjamin Gibert, Helene Lasolle, Laurence Chardon, Jessica Garcia, Gérald Raverot, Léa Payen, Thomas Walter","doi":"10.1530/EO-21-0012","DOIUrl":null,"url":null,"abstract":"Summary: We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing's syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well correlated with the disease course, and cfDNA may be used as a predictive marker and/or as an early marker of response. In addition, the absolute count of atypical cells was elevated upon disease progression.Learning points: cfDNA changes were well correlated with the Cushing's syndrome course and with the tumour burden changes assessed by laboratory markers and by RECIST criteria.cfDNA analysis was used to determine the pharmacogenetic patterns of the present patient.An elevated number of atypical circulating cells was noticed upon disease progression.","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"1 1","pages":"K1-K6"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/b4/EO-21-0012.PMC10265538.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine oncology (Bristol, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/EO-21-0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Summary: We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing's syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well correlated with the disease course, and cfDNA may be used as a predictive marker and/or as an early marker of response. In addition, the absolute count of atypical cells was elevated upon disease progression.

Learning points: cfDNA changes were well correlated with the Cushing's syndrome course and with the tumour burden changes assessed by laboratory markers and by RECIST criteria.cfDNA analysis was used to determine the pharmacogenetic patterns of the present patient.An elevated number of atypical circulating cells was noticed upon disease progression.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

cfDNA在库欣综合征胰腺神经内分泌癌治疗中的作用。

摘要:我们报告一例伴有副肿瘤库欣综合征的转移性胰腺神经内分泌癌，患者先后接受了5种治疗方案(铂-依托泊苷、lv5fu2 -达卡巴嗪、FOLFIRINOX、派姆单抗和紫杉醇)和抗分泌治疗。从二线处理开始，在每次形态学评估时分析循环游离DNA (cfDNA)。cfDNA变化与病程密切相关，cfDNA可作为预测标记物和/或早期反应标记物。此外，非典型细胞的绝对计数随疾病进展而升高。学习要点:cfDNA变化与库欣综合征病程以及实验室标记物和RECIST标准评估的肿瘤负荷变化密切相关。采用cfDNA分析确定本例患者的药物遗传模式。非典型循环细胞的数量随着疾病的进展而增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Endocrine oncology (Bristol, England)

自引率

0.00%

发文量